Dr. Helen Stacey

Internal Medicine
Diablo Clinical Research
2255 Ygnacio Valley Rd Ste M, 
Walnut Creek, CA 
Diablo Clinical Research
2255 Ygnacio Valley Rd Ste M, 
Walnut Creek, CA 

Overview

Helen Stacey is a primary care provider, practicing in Internal Medicine in Walnut Creek, California. Her top areas of expertise are Malabsorption, Maturity Onset Diabetes of the Young, Strep Throat, and Celiac Disease.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

Diablo Clinical Research
2255 Ygnacio Valley Rd Ste M, Walnut Creek, CA 94598

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Patients With Celiac Disease (ACeD)
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Drug
Study Drug: KAN-101
Study Phase: Phase 1
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3437943
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drugs: LY3437943, Dulaglutide
Study Phase: Phase 2
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: November 02, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
Enrollment Status: Completed
Publish Date: July 08, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Biological
Study Drug: Nexvax2
Study Phase: Phase 2
View 9 Less Clinical Trials

6 Total Publications

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age.
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age.
Journal: Vaccines
Published: November 26, 2024
Similar Doctors
Expertise in
28
conditions
Dr. Michael Albert
Internal Medicine
Expertise in
28
conditions
Dr. Michael Albert
Internal Medicine

The Periscope Group

548 Market St, 
San Francisco, CA 
 (22.2 miles away)
212-937-6400
Languages Spoken:
English
See accepted insurances

Michael Albert is a primary care provider, practicing in Internal Medicine in San Francisco, California. Dr. Albert is highly rated in 28 conditions, according to our data. His top areas of expertise are Nijmegen Breakage Syndrome, Wiskott-Aldrich Syndrome, Hyper IgE Syndrome, Splenectomy, and Spinal Fusion.

Stephen Luby
Expertise in
18
conditions
Dr. Stephen Luby
Internal Medicine
Expertise in
18
conditions
Dr. Stephen Luby
Internal Medicine

Office

473 Via Ortega # Y2, 
Stanford, CA 
 (35.7 miles away)
650-723-4129
Languages Spoken:
English

Stephen Luby is a primary care provider, practicing in Internal Medicine in Stanford, California. Dr. Luby is highly rated in 18 conditions, according to our data. His top areas of expertise are Diarrhea, Parainfluenza, Typhoid Fever, and Salmonella Enterocolitis.

Expertise in
10
conditions
Dr. Gregory Kato
Internal Medicine
Expertise in
10
conditions
Dr. Gregory Kato
Internal Medicine

El Camino Health

2500 Grant Rd, 
Mountain View, CA 
 (38.3 miles away)
408-739-6000
Languages Spoken:
English

Gregory Kato is a primary care provider, practicing in Internal Medicine in Mountain View, California. Dr. Kato is highly rated in 10 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Endoscopy, and Gastrostomy.

Frequently Asked Questions about Dr. Helen Stacey

How do I make an appointment with Dr. Helen Stacey?

You can book an appointment with Dr. Helen Stacey by calling their office at 925-930-7267. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Helen Stacey a top-rated expert for Malabsorption?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Helen Stacey is classified as an Experienced expert for Malabsorption, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Helen Stacey specialize in?

While Dr. Helen Stacey is a Internal Medicine, they have specific expertise in Malabsorption, Maturity Onset Diabetes of the Young, and Strep Throat. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Helen Stacey participate in research or clinical trials?

Yes. Dr. Helen Stacey has published 6 articles and abstracts on conditions like Malabsorption. You can view a list of Dr. Helen Stacey's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Helen Stacey accept my insurance?

Dr. Helen Stacey accepts most major insurance plans, including Anthem BCBS and Cigna. We recommend calling the office directly at 925-930-7267 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stacey's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile